What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. 

Our customer sought to increase the titer of a molecule that had proven difficult to express. Use of a single transfection approach had delivered a low titer performance after generation of stable pools. This titer was insufficient to support clinical studies, possibly putting the development program in jeopardy.

Learn about efficient strategies that help you continue the development of your molecule and improve productivity.